Subscribe To
Intra-cellular (itci) q3 earnings top, product sales view raised
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. caplyta sales continue t...
November 3, 2023, 1:32 pm
Intra-cellular therapies reports third quarter 2023 financial results and raises 2023 caplyta sales guidance
Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 caply...
November 2, 2023, 11:30 am
Intra-cellular therapies: caplyta's rise and a promising pipeline
Intra-Cellular Therapies' main drug, caplyta, has been successful in treating neuropsychiatric conditio...
August 12, 2023, 10:29 am
Intra-cellular (itci) q2 earnings & sales top, '23 view raised
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. caplyta sales continue to dr...
August 4, 2023, 9:47 am
Intra-cellular therapies: depression data boosts investment prospects (rating upgrade)
Intra-Cellular's drug caplyta (lumateperone) is advancing through trials for major depressive disorder ...
May 25, 2023, 7:51 pm
Why intra-cellular therapies climbed tuesday
caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potent...
March 28, 2023, 12:27 pm
Intra-cellular (itci) q4 earnings & sales top, caplyta shines
Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues be...
March 2, 2023, 9:47 am
Intra-cellular: hitting a growth inflection (rating upgrade)
Following approval for schizophrenia in late 2019, caplyta then gained its first label expansion for bi...
December 18, 2022, 9:30 am
Intra-cellular's (itci) caplyta aids growth, overdependence a woe
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, caplyta, a...
November 18, 2022, 3:11 pm
Robust uptake of antipsychotic drug boosts intra-cellular's q1 earnings
Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33....
May 10, 2022, 3:04 pm
Intra-cellular; long-term to own with a few fda approvals and ability to expand
caplyta has been approved by the FDA for the treatment of adults with schizophrenia and adults with bip...
March 8, 2022, 3:09 pm